Monoclonal antibodies in the treatment of chronic lymphocytic leukemia

Published: June 8, 2009
Abstract Views: 206
PDF: 182
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The introduction of monoclonal antibodies into the therapeutic arena in chronic lymphocytic leukemia (CLL) has revolutionize the possibility of effective treatment of this indolent condition. The impressive activity of rituximab in the management of lymphoma was obvious early. The usefulness of this antibody in CLL was not as apparent, as in the pivotal clinical trial, small lymphocytic lymphoma (SLL) patients in relapse had a response rate of only 12%. Alemtuzumab when used initially had impressive antitumor activity but very significant toxicity. These two agents are however been built into effective treatment strategies at all ends of the therapeutic spectrum in CLL.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Keating, M. (2009). Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.405